Quest Diagnostics Inc (DGX)
Industry Diagnostics & Research
This stock can be held in an Investment ISA and an Investment Account
Sell
$184.50
Buy
$200.67
$0.33 (+0.17%)
Prices updated at 02 Apr 2026, 22:42 EDT
| Prices minimum 15 mins delay
Prices in USD
Quest Diagnostics Inc provides diagnostic testing, information, and services, providing insights that enable patients and physicians to make healthcare decisions. It provides diagnostics for insurers and healthcare information technology businesses.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Diagnostics & Research
Chairman
Mr. James E. Davis
CEO
Mr. James E. Davis
Most recent earnings
31 Dec 2025
Fiscal year end
31 Dec 2025
Employees
57,000
Head office
500 Plaza Drive
Secaucus
United States
07094
Key personnel
Owner name | Salary |
|---|---|
Mr. Timothy Charles Wentworth Independent Director | - |
Mr. Michael E. Prevoznik Senior Vice President and General Counsel | 0.55m |
Mr. Robert B. Carter Independent Director | 0.07m |
Mr. Timothy M. Ring Lead Independent Director | 0.17m |
Mr. Timothy L. Main Independent Director | 0.13m |
Ms. Denise M. Morrison Independent Director | 0.13m |
Mr. Gary M. Pfeiffer Independent Director | 0.15m |
Mr. Patrick Plewman Senior Vice President, Diagnostic Services | - |
Ms. Vicky B. Gregg Independent Director | 0.13m |
Ms. Catherine T. Doherty Executive Vice President, Regional Businesses | 0.62m |
Mr. James E. Davis Chairman of the Board, President and Chief Executive Officer | 1.25m |
Mr. Sam A. Samad Executive Vice President and Chief Financial Officer | 0.67m |
Dr. Luis A. Diaz, Jr,M.D. Independent Director | 0.12m |
Mr. Michael J. Deppe Senior Vice President, Corporate Controller and Chief Accounting Officer | - |
Mr. Wright L. Lassiter, III Independent Director | 0.12m |
Ms. Tracey C. Doi Independent Director | 0.12m |
Mr. Mark E. Delaney Senior Vice President and Chief Commercial Officer | - |
Mr. Karthik Kuppusamy Senior Vice President, Clinical Solutions | 0.54m |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| Vanguard Group Inc | 14,392,082 |
| BlackRock Inc | 10,002,035 |
| JPMorgan Chase & Co | 8,634,782 |
| T. Rowe Price Associates, Inc. | 7,005,990 |
| T. Rowe Price | 5,326,700 |
Director dealings
Date | Action |
|---|---|
| 25 Nov 2025 | - |
| 25 Nov 2025 | - |
| 25 Nov 2025 | - |
| 25 Nov 2025 | - |
| 25 Nov 2025 | - |
| 25 Nov 2025 | - |
| 18 Nov 2025 | - |
| 18 Nov 2025 | - |
| 18 Nov 2025 | - |
| 18 Nov 2025 | - |
| 18 Nov 2025 | - |
| 05 Nov 2025 | - |
| 22 Oct 2025 | - |
| 23 Oct 2025 | - |
| 21 Oct 2025 | - |
| 21 Oct 2025 | - |
| 21 Oct 2025 | - |
| 21 Oct 2025 | - |
| 21 Oct 2025 | - |
| 21 Oct 2025 | - |
Please note that past performance is not a reliable indicator of future returns.
